PAPPA and preeclampsia: Several studies have suggested that additional biomarkers such as PP13, pregnancy-associated plasma protein-A (PaPP-A), placental growth factor (PIGF), along with uterine artery Doppler and biophysical feature combined with prophylactic aspirin for those classified as high risk of preterm preeclampsia (preeclampsia resulting in a iatrogenic delivery before 37 weeks of gestation) to be cost effective and even cost saving [11–13].